Gut-brain biotech Kallyope ramps up, bags $66M series B

Retrieved on: 2018-02-21 21:18:45

Tags for this article:

Brain

Nancy Thornberry

Chemogenetics

Steatohepatitis

Click the tags to see associated articles and topics

Gut-brain biotech Kallyope ramps up, bags $66M series B. View article details on hiswai:

Excerpt

<div>All of its series A investors—which include <b>Lux Capital</b>, Polaris Partners, The Column Group, Illumina Ventures and Alexandria Venture Investments—participated in the latest round. Kallyope CEO Nancy Thornberry kept mum on the details at launch, saying simply, “"Our goal is to develop an industry ...</div>

Article found on:

View Original Article